The study and its comparison
Seventy-two people with Parkinson disease and constipation were randomized to multistrain probiotic capsules or placebo for four weeks. Daily stool diaries supplied the primary outcome. [1]
The between-group difference was about 1.3 additional spontaneous bowel movements per week. Stool consistency and constipation-related quality of life also improved, while fecal calprotectin did not change significantly. [1]
What the finding establishes
A bowel benefit is different from a disease-modifying neurological effect. The short study does not rank all probiotic products or establish long-term safety. One probiotic recipient withdrew with a nonserious adverse event. Funding and conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine constipation improves while neurodegeneration is not measured. The bowel result should retain its actual meaning.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.